TP53 and neoplasm: We further demonstrated that targeting both USP7 and USP22 leads to a synergistic effect through modulating multiple important tumor suppressor and oncogenic pathways including p53 and c-Myc, underscoring the therapeutic potential of targeting both USP7 and USP22.